What does the evidence say about Lycopene Blood Pressure Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Lycopene Blood Pressure Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Background : Carotid intima-media thickness (IMT) is a well-established surrogate marker of subclinical atherosclerosis and a predictor of cardiovascular risk. [Cavero-Redondo I (2026); evidence level 1] - Carotenoids, particularly lycopene and β-carotene, have been proposed as protective antioxidants against vascular damage, but evidence from population-based studies is inconsistent. [Cavero-Redondo I (2026); evidence level 1] - Subgroup and meta-regression analyses explored potential modifiers, including sex and cardiovascular risk factors. [Cavero-Redondo I (2026); evidence level 1] - Tomato intake improved selective attention (concentration performance: +7.2 points; processing speed: +8.3 points) and associative memory (face-name matching: +0.8 points). [López-Solís R (2026); evidence level 2] - Resting-state fMRI revealed changes in brain networks, including reduced connectivity in frontoparietal and auditory networks, contrasting with reductions in the dorsal attention network during the control period. [López-Solís R (2026); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.